Design and validation of a predictive model for 1-year hospital admission in HIV patients on antiretroviral treatment

Background. The health crisis due to the COVID-19 pandemic is a challenge in the dispensing of outpatient hospital medication (OHM). Models of Antiretroviral Therapy (ART) based on community pharmacy support (ARTCP) have proven to be successful. The aim was to evaluate the degree of satisfaction, acceptability and limitations of the implementation of ARTCP, in the context of a pandemic, in our environment. Methods. Descriptive cross-sectional study carried out in a Barcelona hospital, during the months of July-November 2020. A telephone survey was carried out via a questionnaire on the quality dimensions of the model (degree of satisfaction, acceptability) and associated inconveniences. Data collected: demographics, antiretroviral treatment (ART), concomitant medication, drug interactions (DDIs), CD4 lymphocyte count and plasma viraemia. Data analysis included descriptive statistics. Results. A total of 533 (78.0%) HIV patients receiving ART were included. 71.9% (383/533) of these patients were very satisfied and 76.2% preferred attending the community pharmacy rather than the hospital. The mean satisfaction rating was 9.3 (DS: 1.4). The benefits reported were: 1) proximity to home (406: 76.1%); 2) lower risk of contagion of COVID-19 (318: 59.7%); 3) shorter waiting time (201: 37.1%); 4) time flexibility (104: 19.5%); 5) reduction of financial expenses (35: 6.57%). A total of 11 (2%) patients reported no benefit. Only 22.9% reported disadvantages associated with ARTCP: 1) lack of privacy (65: 12.2%); 2) lack of coordinationorganization (57: 10.7%). Conclusion. The COVID-19 pandemic has had an impact on the provision of pharmaceutical care for HIV patients. The ARTPC model has proved efficient, with patients reporting a high degree of satisfaction.

Download Full-text

Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors

ISRN AIDS ◽

10.5402/2012/621565 ◽

2012 ◽

Vol 2012 ◽

pp. 1-8 ◽

Cited By ~ 20

Author(s):

Assane Diouf ◽

Amandine Cournil ◽

Khadidiatou Ba-Fall ◽

Ndèye Fatou Ngom-Guèye ◽

Sabrina Eymard-Duvernay ◽

...

Keyword(s):

Risk Factors ◽

Cardiovascular Risk ◽

Cardiovascular Risk Factors ◽

Antiretroviral Treatment ◽

Cross Sectional Study ◽

Older Age ◽

World Health ◽

Resource Constrained ◽

Hiv Patients ◽

Cross Sectional

Cardiovascular risk factors in people on antiretroviral treatment (ART) are poorly documented in resource-constrained settings. A cross-sectional study was conducted in 2009 to assess prevalence of diabetes and hypertension in a sample of 242 HIV-infected patients who had initiated ART between 1998 and 2002 in Dakar, Senegal (ANRS 1215 observational cohort). World Health Organization (WHO) criteria were applied to diagnose diabetes and hypertension. Multiple logistic regressions were used to identify factors associated with diabetes and hypertension. Patients had a median age of 46 years and had received ART for a median duration of about 9 years. 14.5% had diabetes and 28.1% had hypertension. Long duration of ART (≥119 months), older age, higher body mass index (BMI), and higher levels of total cholesterol were associated with higher risks of diabetes. Older age, higher BMI at ART initiation, and higher levels of triglycerides were associated with higher risk of hypertension. This study shows that diabetes and hypertension were frequent in these Senegalese HIV patients on ART. It confirms the association between duration of ART and diabetes and highlights the need to implement programs for prevention of cardiovascular risk factors in HIV patients from resource-constrained settings.

Download Full-text

PS-034 Hypophosphatemia in HIV patients treated with antiretroviral treatment

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2015-000639.360 ◽

2015 ◽

Vol 22 (Suppl 1) ◽

pp. A149.3-A150

Author(s):

MA Pedrosa Naudín ◽

E Briones Cuesta ◽

CJ Dueñas Gutierrez ◽

M Güemes Garcia ◽

MA Machín Morón

Keyword(s):

Antiretroviral Treatment ◽

Hiv Patients

Download Full-text

Breaks from antiretroviral treatment are not the answer for HIV patients

BMJ ◽

10.1136/bmj.327.7414.520-c ◽

2003 ◽

Vol 327 (7414) ◽

pp. 520-c-0 ◽

Cited By ~ 1

Author(s):

D. Josefson

Keyword(s):

Antiretroviral Treatment ◽

Hiv Patients

Download Full-text

Suboptimal Immune Reconstitution among HIV-Infected Saudi Patients following Successful Antiretroviral Treatment

Canadian Journal of Infectious Diseases and Medical Microbiology ◽

10.1155/2019/1842106 ◽

2019 ◽

Vol 2019 ◽

pp. 1-8

Author(s):

Fahad Al-Majid ◽

Zahid Shakoor ◽

Mazin Barry

Keyword(s):

Viral Load ◽

Immune Reconstitution ◽

Antiretroviral Treatment ◽

Population Expansion ◽

Hiv Viral Load ◽

Hiv Patients ◽

Delayed Treatment ◽

Hla Dr ◽

Before And After ◽

Saudi Patients

Background and Objectives. Variations in immune reconstitution following antiretroviral treatment (ART) among HIV patients have previously been observed. This study aims at assessing immune reconstitution after successful ART among HIV-infected Saudi patients.Methods. This retrospective study of 240 HIV-infected patients was performed between May 2010 and June 2015 in the HIV center at King Saud Hospital, Riyadh. Data were extracted for CD4, CD8 cell, and CD3/HLA-DR counts along with the viral load from patient records before and after four years of successful ART. The inclusion criterion was patients with CD4 reconstitution of either equal to or more than 400 cells/mm3with an undetectable HIV viral load following ART. Based on their presentation, the HIV patients were grouped into early treatment (ET) and delayed treatment (DT) groups with CD4 counts of 200–350 cells/mm3and less than 200 cells/mm3, respectively.Findings. The pretreatment CD8+ counts of median 865 cells/mm3(interquartile range (IQR) 774–1072) in the DT group declined to median 753 cells/mm3(IQR 574–987;p<0.0001). Moreover, there was a decline in CD8 counts from 703 cells/mm3(IQR 655–747) to 620 cells/mm3(IQR 563–645;p<0.04) in the ET group after four years of successful ART. Pretreatment activation marker (CD3/HLA-DR+) expression of median 29% in the DT group declined to 22% and in the ET group from a median of 23% to 19% after treatment. The CD4/CD8 ratio in the DT group increased from 0.14 (IQR 0.09–0.88) to 0.71 (IQR 0.54–0.9) and from 0.42 (IQR 0.35–0.55) to 0.87 (IQR 0.71–0.98) in the ET group.Conclusion. Immune reconstitution after successful ART among HIV-infected Saudi patients was associated with a CD8 T-cell population expansion with a suboptimal CD4/CD8 ratio and persistent immune activation. Early initiation of ART appears to favorably influence the CD4/CD8 ratio.

Download Full-text